Myanmar Experience with Serum IGF-1, Salmon Calcitonin and Postmenopausal Osteoporosis

• Published in: International journal of bioscience, biochemistry, bioinformatics (IJBBB) biochemistry, bioinformatics (IJBBB), 2011-05, Vol.1 (1), p.32-36
• Main Authors: Fics, Hein Latt Win, Sunn, Hta Kyi, Myint, Theingi, Phil, Myo Win M.
• Format: Article
• Language: English
• Subjects: Salmonidae
• ISSN: 2010-3638; 2010-3638
• DOI: 10.7763/IJBBB.2011.V1.6

A great deal of information has been obtained onthe system of growth hormone and IGF-1 in development ofosteoporosis. The imbalance of this system may be the cause ofdiseases of neonatal period as well as disease associated withaging. In old age, the synthesis of IGF - 1 declines as well as theaction of this peptide on tissues. The aim of this study is to findout the association between serum IGF-1 levels and bonemineral density. Sixty postmenopausal non osteoporoticwomen and sixty postmenopausal osteoporotic women wereselected for this study. Out of 60 cases, 50 postmenopausalosteoporotic women completed the study. Bone mineral density(BMD) of postmenopausal women with symptom ofosteoporosis was measured by ultrasonic bone densitometry(UBIS5000).Postmenopausal women with BMD results of Tscore less than or equal to - 2.5 were selected as cases and that of > - 1 wereselected as controls. Serum IGF -1 level was measured byELISA method after removal of IGFBP from IGF - 1. In thisstudy, both base line BMD and serum IGF-1 level of theosteoporotic women were significantly lower than that of nonosteoporotic women (p < 0.05). BMD and serum IGF-1 level in3 months after calcitonin injection of osteoporotic women weresignificantly higher (p < 0.001) than that of baseline BMD andserum IGF-1 level. There was positive correlation betweenbaseline serum IGF-1 and BMD level in postmenopausalosteoporotic women (r = 0.470, p = 0.001) as well as in control(r = 0.288, p= 0.025). It is hoped that this study will serve asground for further study in the related fields, and thus, as partfor the development of applications in the management ofpostmenopausal osteoporotic women.